Who
Lawrence Steinman
Director
Company insider
Files Form 4 as: Director, Pasithea Therapeutics; Director, BioAtla; Director, Forum Markets; Director, Atreca.
In numbers
- Trades disclosed
- 42
- Buys
- 5
- Sells
- 4
- Bought
- $197K
- Sold
- $66K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 24 Jun 2019
- Last trade
- 1 May 2026
- Last filed
- 5 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 5 May 2026 | KTTA Pasithea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,783 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | KTTA Pasithea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —152,783 at $0.00 | filing |
| 28 Nov 2025filed 1 Dec 2025 | KTTA Pasithea TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K133,333 at $0.75 | filing |
| 24 Oct 2025filed 27 Oct 2025 | KTTA Pasithea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —242,913 at $0.00 | filing |
| 18 Jun 2025filed 18 Jun 2025 | BioAtlaBiotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 17 Jun 2025filed 30 Jun 2025 | FRMM Forum Marketsoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 17 Jun 2025filed 30 Jun 2025 | FRMM Forum MarketsConsumer & Specialty Finance | SEC FORM 4 Code A | —44,959 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | FRMM Forum Marketsoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | FRMM Forum MarketsConsumer & Specialty Finance | SEC FORM 4 Code A | —48,198 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | FRMM Forum MarketsConsumer & Specialty Finance | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | BioAtlaBiotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 1 Mar 2024filed 5 Apr 2024 | KTTA Pasithea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 1 Mar 2024filed 1 Mar 2024 | KTTA Pasithea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 19 Dec 2023filed 19 Dec 2023 | BioAtlaBiotechnology | SEC FORM 4 Bought | $41K20,000 at $2.05 | filing |
| 4 Sep 2023filed 6 Sep 2023 | FRMM Forum Marketsoption or derivative · Consumer & Specialty Finance | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | BioAtlaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | KTTA Pasithea TherapeuticsBiotechnology | SEC FORM 4 Bought | $13K30,000 at $0.43 | filing |
| 1 Jun 2023filed 2 Jun 2023 | FRMM Forum MarketsConsumer & Specialty Finance | SEC FORM 4 Bought | $22K18,000 at $1.23 | filing |
| 28 Nov 2022filed 28 Nov 2022 | KTTA Pasithea TherapeuticsBiotechnology | SEC FORM 4 Code A | $4,9005,000 at $0.98 | filing |
| 22 Nov 2022filed 22 Nov 2022 | KTTA Pasithea TherapeuticsBiotechnology | SEC FORM 4 Code A | $4,9505,000 at $0.99 | filing |
News
No headline names them, or the companies they trade most, lately.